{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:56:49Z","timestamp":1791111409331,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s00228-011-1094-4","type":"journal-article","created":{"date-parts":[[2011,7,7]],"date-time":"2011-07-07T15:47:59Z","timestamp":1310053679000},"page":"29-37","source":"Crossref","is-referenced-by-count":42,"title":["The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine"],"prefix":"10.1007","volume":"68","author":[{"given":"Junichi","family":"Azuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Hasunuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Miyatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiko","family":"Koue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koushi","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamiki","family":"Katano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumiko","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,7,8]]},"reference":[{"key":"1094_CR1","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1021\/jm940608g","volume":"41","author":"Y Oshiro","year":"1998","unstructured":"Oshiro Y, Sato S, Kurahashi N, Tanaka T, Kikuchi T, Tottori K, Uwahodo Y, Nishi T (1998) Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives. J Med Chem 41:658\u2013667","journal-title":"J Med Chem"},{"key":"1094_CR2","unstructured":"Otsuka Pharmaceutical Co, Ltd (2009) Package insert of Abilify\u00ae (aripiprazole, U.S.), July 2009 revision. Otsuka, Tokyo"},{"key":"1094_CR3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/00003088-199427030-00002","volume":"27","author":"E Perucca","year":"1994","unstructured":"Perucca E, Gatti G, Spina E (1994) Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet 27:175\u2013190","journal-title":"Clin Pharmacokinet"},{"key":"1094_CR4","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2165\/00003088-199733060-00004","volume":"33","author":"BA Sproule","year":"1997","unstructured":"Sproule BA, Naranjo CA, Brenmer KE, Hassan PC (1997) Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet 33:454\u2013471","journal-title":"Clin Pharmacokinet"},{"key":"1094_CR5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s002280050163","volume":"51","author":"U Jeppesen","year":"1996","unstructured":"Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Br\u00f8sen K (1996) Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51:73\u201378","journal-title":"Eur J Clin Pharmacol"},{"key":"1094_CR6","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1124\/dmd.105.004077","volume":"33","author":"K Venkatakrishnan","year":"2005","unstructured":"Venkatakrishnan K, Obach RS (2005) In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Dispos 33:845\u2013852","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 1","key":"1094_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199500291-00003","volume":"29","author":"J Harten van","year":"1995","unstructured":"van Harten J (1995) Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet 29(Suppl 1):1\u20139","journal-title":"Clin Pharmacokinet"},{"key":"1094_CR8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF00195913","volume":"46","author":"JC Fleishaker","year":"1994","unstructured":"Fleishaker JC, Hulst LK (1994) A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 46:35\u201339","journal-title":"Eur J Clin Pharmacol"},{"key":"1094_CR9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s002280050655","volume":"55","author":"P Damkier","year":"1999","unstructured":"Damkier P, Hansen LL, Br\u00f8sen K (1999) Effect of fluvoxamine on the pharmacokinetics of quinidine. Eur J Clin Pharmacol 55:451\u2013456","journal-title":"Eur J Clin Pharmacol"},{"key":"1094_CR10","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1177\/0091270003259216","volume":"43","author":"YW Lam","year":"2003","unstructured":"Lam YW, Alfaro CL, Ereshefsky L, Miller M (2003) Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J Clin Pharmacol 43:1274\u20131282","journal-title":"J Clin Pharmacol"},{"key":"1094_CR11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1365-2125.1996.tb00019.x","volume":"42","author":"ZH Xu","year":"1996","unstructured":"Xu ZH, Xie HG, Zhou HH (1996) In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br J Clin Pharmacol 42:518\u2013521","journal-title":"Br J Clin Pharmacol"},{"key":"1094_CR12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00007691-199306000-00011","volume":"15","author":"E Spina","year":"1993","unstructured":"Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP (1993) Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 15:243\u2013246","journal-title":"Ther Drug Monit"},{"key":"1094_CR13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2133\/dmpk.20.55","volume":"20","author":"M Kubo","year":"2005","unstructured":"Kubo M, Koue T, Inaba A, Takeda H, Maune H, Fukuda T, Azuma J (2005) Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab Pharmacokin 20:55\u201364","journal-title":"Drug Metab Pharmacokin"},{"key":"1094_CR14","unstructured":"US FDA (2002) Drug approval package, Abilify (aripiprazole) tablets. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2002\/21-436_Abilify.cfm"},{"key":"1094_CR15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2133\/dmpk.19.83","volume":"19","author":"S Ozawa","year":"2004","unstructured":"Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, Koyano S, Sai K, Ohno Y, Saito Y, Sawada J (2004) Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As, and MDR1\/ABCB1. Drug Metab Pharmacokinet 19:83\u201395","journal-title":"Drug Metab Pharmacokinet"},{"key":"1094_CR16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2133\/dmpk.15.165","volume":"15","author":"T Fukuda","year":"2000","unstructured":"Fukuda T, Azuma J (2000) Evaluation of in vivo and in vitro metabolic characteristics of CYP2D6*10. Drug Metab Pharmacokinet 15:165\u2013170","journal-title":"Drug Metab Pharmacokinet"},{"key":"1094_CR17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2133\/dmpk.22.358","volume":"22","author":"M Kubo","year":"2007","unstructured":"Kubo M, Koue T, Maune H, Fukuda T, Azuma J (2007) Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet 22:358\u2013366","journal-title":"Drug Metab Pharmacokinet"},{"key":"1094_CR18","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.1985.194","volume":"38","author":"K Nakamura","year":"1985","unstructured":"Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38:402\u2013408","journal-title":"Clin Pharmacol Ther"},{"key":"1094_CR19","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2125.1987.tb03080.x","volume":"23","author":"T Ishizaki","year":"1987","unstructured":"Ishizaki T, Eichelbaum M, Horai Y, Hashimoto K, Chiba K, Dengler HJ (1987) Evidence for polymorphic oxidation of sparteine in Japanese subjects. Br J Clin Pharmacol 23:482\u2013485","journal-title":"Br J Clin Pharmacol"},{"key":"1094_CR20","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/clpt.1989.126","volume":"46","author":"Y Horai","year":"1989","unstructured":"Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BI, Liao CL, Zhang LM (1989) Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 46:198\u2013207","journal-title":"Clin Pharmacol Ther"},{"issue":"1\u20132","key":"1094_CR21","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jchromb.2005.06.023","volume":"822","author":"M Kubo","year":"2005","unstructured":"Kubo M, Mizooku Y, Hirao Y, Osumi T (2005) Development and validation of an LC-MS\/MS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 822(1\u20132):294\u2013299","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"1094_CR22","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2133\/dmpk.20.294","volume":"20","author":"A Ebisawa","year":"2005","unstructured":"Ebisawa A, Hiratsuka M, Sakuyama K, Konno Y, Sasaki T, Mizugaki M (2005) Two novel single nucleotide polymorphisms (SNPs) of the CYP2D6 gene in Japanese individuals. Drug Metabol Pharmacokinet 20:294\u2013299","journal-title":"Drug Metabol Pharmacokinet"},{"key":"1094_CR23","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1124\/dmd.108.023242","volume":"36","author":"K Sakuyama","year":"2008","unstructured":"Sakuyama K, Sasaki T, Ujiie S, Obata K, Mizugaki M, Ishikawa M, Hiratsuka M (2008) Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A\u2013B, 18, 27, 36, 39, 47\u201351, 53\u201355, and 57). Drug Metab Dispos 36:2460\u20132467","journal-title":"Drug Metab Dispos"},{"key":"1094_CR24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1124\/mol.64.1.42","volume":"64","author":"GR Robertson","year":"2003","unstructured":"Robertson GR, Field J, Goodwin B, Bierach S, Tran M, Lehnert A, Liddle C (2003) Transgenic mouse models of human CYP3A4 gene regulation. Mol Pharmacol 64:42\u201350","journal-title":"Mol Pharmacol"},{"key":"1094_CR25","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2133\/dmpk.22.358","volume":"22","author":"M Kubo","year":"2007","unstructured":"Kubo M, Koue T, Fukuda T, Azuma J (2007) Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet 22:358\u2013366","journal-title":"Drug Metab Pharmacokinet"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00228-011-1094-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T20:35:30Z","timestamp":1560371730000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-011-1094-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,8]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["1094"],"URL":"https:\/\/doi.org\/10.1007\/s00228-011-1094-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,8]]}}}